Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

1.

Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.

Lu H, Tu W, Fei H, Xu G, Hu Q, Zhang L, Lin B, Yuan J, Yin J, Gong A, Wan M, Wang D, Zhu X, Feng J, Wang Q, Sun P.

Bioorg Med Chem Lett. 2014 Jun 1;24(11):2555-9. doi: 10.1016/j.bmcl.2014.03.086. Epub 2014 Apr 3.

PMID:
24755426
[PubMed - in process]
2.

Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.

Kiga M, Tanzawa F, Iwasaki S, Inaba F, Fujiwara K, Iwadare H, Echigo T, Nakamura Y, Shibata T, Suzuki K, Yasumatsu I, Nakayama A, Sasazawa Y, Tashiro E, Imoto M, Kurakata S.

Anticancer Drugs. 2012 Jan;23(1):119-30. doi: 10.1097/CAD.0b013e32834c6a33.

PMID:
22008853
[PubMed - indexed for MEDLINE]
3.

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.

Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.

Int J Cancer. 2013 Nov;133(9):2089-101. doi: 10.1002/ijc.28236. Epub 2013 May 29.

PMID:
23629727
[PubMed - indexed for MEDLINE]
4.

Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.

Isshiki Y, Kohchi Y, Iikura H, Matsubara Y, Asoh K, Murata T, Kohchi M, Mizuguchi E, Tsujii S, Hattori K, Miura T, Yoshimura Y, Aida S, Miwa M, Saitoh R, Murao N, Okabe H, Belunis C, Janson C, Lukacs C, Schück V, Shimma N.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1795-801. doi: 10.1016/j.bmcl.2011.01.062. Epub 2011 Jan 21.

PMID:
21316218
[PubMed - indexed for MEDLINE]
5.

Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.

Daouti S, Wang H, Li WH, Higgins B, Kolinsky K, Packman K, Specian A Jr, Kong N, Huby N, Wen Y, Xiang Q, Podlaski FJ, He Y, Fotouhi N, Heimbrook D, Niu H.

Cancer Res. 2009 Mar 1;69(5):1924-32. doi: 10.1158/0008-5472.CAN-08-2627. Epub 2009 Feb 24.

PMID:
19244124
[PubMed - indexed for MEDLINE]
Free Article
6.

Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.

Miranda MB, McGuire TF, Johnson DE.

Leukemia. 2002 Apr;16(4):683-92.

PMID:
11960350
[PubMed - indexed for MEDLINE]
Free Article
7.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

PMID:
20130576
[PubMed - indexed for MEDLINE]
8.

MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1.

Ding XZ, Adrian TE.

Biochem Biophys Res Commun. 2001 Mar 30;282(2):447-53.

PMID:
11401480
[PubMed - indexed for MEDLINE]
9.

MEK1/2 inhibitors in the treatment of gynecologic malignancies.

Miller CR, Oliver KE, Farley JH.

Gynecol Oncol. 2014 Apr;133(1):128-37. doi: 10.1016/j.ygyno.2014.01.008. Epub 2014 Jan 14. Review.

PMID:
24434059
[PubMed - indexed for MEDLINE]
10.

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR.

Clin Cancer Res. 2009 Jul 15;15(14):4649-64. doi: 10.1158/1078-0432.CCR-09-0317. Epub 2009 Jun 30.

PMID:
19567590
[PubMed - indexed for MEDLINE]
Free Article
11.

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA.

Cancer Res. 2004 Oct 1;64(19):7099-109.

PMID:
15466206
[PubMed - indexed for MEDLINE]
Free Article
12.

The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes.

Talarmin H, Rescan C, Cariou S, Glaise D, Zanninelli G, Bilodeau M, Loyer P, Guguen-Guillouzo C, Baffet G.

Mol Cell Biol. 1999 Sep;19(9):6003-11.

PMID:
10454547
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery.

Okano J, Rustgi AK.

J Biol Chem. 2001 Jun 1;276(22):19555-64. Epub 2001 Mar 5.

PMID:
11278851
[PubMed - indexed for MEDLINE]
Free Article
14.

Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.

Champelovier P, El Atifi M, Pautre V, Rostaing B, Berger F, Seigneurin D.

Exp Hematol. 2008 Jan;36(1):28-36. Epub 2007 Oct 18.

PMID:
17949889
[PubMed - indexed for MEDLINE]
15.

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.

J Cell Physiol. 2006 May;207(2):420-7.

PMID:
16419029
[PubMed - indexed for MEDLINE]
16.

Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.

Mallon R, Feldberg L, Kim S, Collins K, Wojciechowicz D, Kohler C, Kovacs D, Discafani C, Zhang N, Wu B, Floyd B, Powell D, Berger D.

Mol Cancer Ther. 2004 Jun;3(6):755-62.

PMID:
15210862
[PubMed - indexed for MEDLINE]
Free Article
17.

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis.

Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E.

BMC Gastroenterol. 2003 Aug 8;3:19.

PMID:
12906713
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

CTGF/Hcs24 induces chondrocyte differentiation through a p38 mitogen-activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extracellular-signal regulated kinase (ERK).

Yosimichi G, Nakanishi T, Nishida T, Hattori T, Takano-Yamamoto T, Takigawa M.

Eur J Biochem. 2001 Dec;268(23):6058-65.

PMID:
11732999
[PubMed - indexed for MEDLINE]
Free Article
19.

Ras-dependent and -independent pathways target the mitogen-activated protein kinase network in macrophages.

Büscher D, Hipskind RA, Krautwald S, Reimann T, Baccarini M.

Mol Cell Biol. 1995 Jan;15(1):466-75.

PMID:
7799956
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk